VAC2

AcronymDefinition
VAC2Valve Anti Cheat 2 (Counter Strike video game)
References in periodicals archive ?
Lineage's clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.
VAC2 is a non-patient-specific, or allogeneic, cancer immunotherapy candidate.
VAC2 currently is being investigated in a Phase 1 study for the treatment of NSCLC and is sponsored and conducted by Cancer Research UK.
VAC2 is potentially complementary and synergistic with other immune therapies such as immune checkpoint inhibitors.
--Oncology--A Phase 2/3 ready cancer vaccine (VAC 1) with an opportunity to continue the development of a second approach using dendritic cells derived from hESCs (VAC2).
BioTime's clinical assets include (i) OpRegen, a retinal pigment epithelium transplant therapy in Phase I/IIa development for the treatment of dry age-related macular degeneration, a leading cause of blindness in the developed world; (ii) OPC1, an oligodendrocyte progenitor cell therapy in Phase I/IIa development for the treatment of acute spinal cord injuries and (iii) VAC2, an allogeneic cancer immunotherapy of antigen-presenting dendritic cells currently in Phase I development for the treatment of non-small cell lung cancer.
--Oncology--A Phase 2/3 ready cancer vaccine (VAC1) with an opportunity to continue the development of a second approach using dendritic cells derived from hESCs (VAC2).